XNK Therapeutics AB (“XNK”) today announced its European patent for the process of expanding NK cells has been validated in 18 countries across the region.
The patent covers XNK’s production methods for expansion and activation of a patient’s own NK cells, which are later given back to the patient to treat cancer. The patent is valid until 2030.
“Receiving a patent for the way we produce the NK cells for our treatments and validating it broadly across Europe is a great step forward for us as we continue to prepare XNK for the future,” said Karin Mellström, CEO of XNK Therapeutics.
For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit xnktherapeutics.com.
About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.
